^
    9ms
    KEYNOTE-D26: Clinical Study of BDB018: Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=1, Completed, Eikon Therapeutics | Active, not recruiting --> Completed | Trial completion date: Mar 2025 --> Sep 2024 | Trial primary completion date: Dec 2024 --> Mar 2024
    Trial completion • Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • BDB018
    almost2years
    KEYNOTE-D26: Clinical Study of BDB018: Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=1, Active, not recruiting, Eikon Therapeutics | Trial completion date: Mar 2024 --> Mar 2025 | Trial primary completion date: Dec 2023 --> Dec 2024
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • BDB018
    over2years
    Clinical Study of BDB018: Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=1, Active, not recruiting, Eikon Therapeutics | Recruiting --> Active, not recruiting | N=50 --> 1 | Trial completion date: Dec 2023 --> Mar 2024 | Trial primary completion date: Mar 2023 --> Dec 2023
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • BDB018